Ecf2016

16 - 18 May 2016

[[1]]

---

Venue [[2]]

Closest rail station: [[3]]

Objectives

1. Review the past 12 months, products, results delivered
2. Plan the next 24 months, products, deliverables
3. Get inputs from the External Advisory Committee and Funding agencies
4. Propose improvements to consortium operation

Agenda

Day 1 Monday 1 February

0900	Session 1. Opening, welcome, objectives	Vish Nene
	Agenda, process, introductions	Peter Ballantyne
1000	Session 2. Consortium ‘annual report’	Vish Nene
1030	Break
1100	Session 3. Revisiting the 2015 meeting – plans, results; what we said we would do!	Interactive exercise
1200	Session 4. Year 2 in review – the research teams * Objective 1: To improve aspects of the current live infection and treatment method ECF vaccine * Objective 2: To induce antibody based immunity by targeting the sporozoite stage of the parasite. * Objective 3: To induce T-cell mediated immunity by targeting the schizont stage of the parasite * Objective 4: Application of evolutionary and comparative pathogen genomics to ECF vaccinology Convenors: * Obj 1: Jeremy * Ob 2: Vish * Ob 3: Ivan * Ob 4: Joana	4 parallel conversations to co-generate 2015 research highlights per objective on PPT to present on day 2 - Results - Insights - Conclusions - Significance - Plans
1300	Lunch
1400	Session 4. Year 2 in review – the research teams Convenors: * Obj 1: Jeremy * Ob 2: Vish * Ob 3: Ivan * Ob 4: Joana	4 parallel conversations to co-generate 2015 research highlights per objective on PPT to present on day 2 - Results - Insights - Conclusions - Significance - Plans
1600	Break
1630	Session 5. Year 2 in review – The focus groups * Group 1: Infectivity assay of sporozoites - Ine * Group 2: Immune responses to p67 - Vish * Group 3: Sporozoite antigen discovery – Lucilla * Group 4: Reagents – communal resources – Lotte * Group 5: Schizont antigen discovery - Tim * Group 6: T. parva genome resources - Joana * Group 7: Antigen delivery systems - Don * Group 8: Proof-of concept - Ivan	Two sets of parallel conversations on each focus group area on PPT to present on day 2: - Results - Activities - Conclusions - Plans
1745	Report from the recent Oxford meeting	Vish
1815	Session 6. EAC member feedback – seen and heard so far	Feedback
1830	END of day 1
	Zebu Club option

Day 2 Tuesday, 2 February

0830	Recap and plans for the day
0845	Session 7. ECF research highlights * Proteomics of MHC class I-associated peptides by Nicola * BHV4 as an antigen delivery system by Gaetano * Construction of p67C nanoparticles by Vish
0915	Session 8. Year 2 in review / year 3 in prospect – Short (10 min) presentations by research teams by objectives * Obj 1: Jeremy * Ob 2: Vish * Ob 3: Ivan * Ob 4: Joana	For each: - Results - Insights - Conclusions - Significance - Plans Q&A
1045	Break
1115	Session 9. Year 2 in review / year 3 in prospect – Short (5 min) presentations by the focus groups	For each: - Results - Activities - Plans Q&A
1215	Session 10. Years 3 and 4 results framework validation and confirmation of expected activities and roles – by objectives	Group work
1300	Lunch
1400	Session 11. Delivering program goals – years 3 and 4 critical program-level milestones and success factors	Interactive exercise
1445	Idea for 2016: Workshop on next gen seq in the context of a vet vaccine network meeting that took place in Roslin	Tim/Ivan
1500	Break
1530	Session 12a. Program management meeting (PMC and EAC members) Session 12b. Inter-lab conversations	Members Others
1730	Brief reports from session 12
1800	Session 13. EAC member feedback – seen and heard so far	Feedback
1830	END of Day 2
1830	Barbecue on campus

DAY 3 Wednesday, 3 February

0830	Recap and plans for the day
0845	Session 14. Documenting program results and outputs
0900	Work on products, blogposts, photo-reports, interviews
1300	Lunch
1400	Work on products
1600	Session 15. Products show and tell Plenary on communicating the consortium’s work
1700	Session 16. Closing – comments from EAC, investors, management, participants
1730	END of day 3

Participants

		ECF CONSORTIUM MEETING
Name	Institution	Email address
Vish Nene	ILRI	[v.nene@cgiar.org]
Lucilla Steinaa	ILRI	[l.steinaa@cgiar.org]
Nicholas Svitek	ILRI	[n.svitek@cgiar.org]
David Kiereini	ILRI	[d.kiereini@cgiar.org]
James Nyagwange	ILRI	[j.nyagwange@cgiar.org]
Sam Oyolla	ILRI	[s.oyola@cgiar.org]
Peter Ballantyne	ILRI	[p.ballantyne@cgiar.org]
Don Knowles	Washington State University/USDA-ARS	[dknowles@vetmed.wsu.edu]
Joana Da Silva	Institute of Genome Sciences-Uni of Maryland	[jcsilva@som.umaryland.edu]
Kyle Tretina	Institute of Genome Sciences-Uni of Maryland	[kyletretina@gmail.com]
Dirk Werling	Royal Veterinary College, London	[Dwerling@RVC.AC.UK]
Ivan Morrison	University of Edinburgh	[ivan.morrison@roslin.ed.ac.uk]
Tim Connelley	University of Edinburgh	[timothy.connelley@roslin.ed.ac.uk]
Fred Fellouse	University of Toronto	[fellouse@gmail.com]
Nicola Ternette	University of Oxford	[nicola.ternette@ndm.ox.ac.uk]
Jeremy Salt	Galvmed	[Jeremy.Salt@galvmed.org]
George Chaka	CTTBD - Malawi	[mihji_chaka2@yahoo.co.uk]
Ine De Goyse	ITM Antwerp	[idegoeyse@itg.be]
Dirk Geysen	ITM Antwerp	[dgeysen@itg.be]
Morten Nielsen	Fundacion Instituto Investigaciones Biotecnologicas (FIIB) Argentina/Technical Univesity of Denmark	[mniel@cbs.dtu.dk]
Niall MacHugh	University of Edinburgh	[niall.machugh@roslin.ed.ac.uk]
ECF EAC
Simon Draper	University of Oxford	[simon.draper@ndm.ox.ac.uk]
Shahid Khan	Leiden University, Netherlands	[S.M.Khan@lumc.nl]
Tomas Hanke	University of Oxford	[tomas.hanke@ndm.ox.ac.uk]
BMGF & USAID/USDA-ARS
Nick Juleff	Bill and Melinda Gates Foundation	[Nick.Juleff@gatesfoundation.org]
Gaetano Donofrio	University Of Parma	[gaetano.donofrio@unipr.it]
Lindsay Fry	Washington State University	[lfry@vetmed.wsu.edu]
Lindsay Parish	USAID	[lparish@usaid.gov]
William Davis	Washington State University	[davisw@vetmed.wsu.edu]